ANALYSES OF HEALTHCARE RESOURCE UTILIZATION (HCRU) IN CHECKMATE 141, A PHASE 3 STUDY OF NIVOLUMAB VERSUS INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) PLATINUM-REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

被引：0
|
作者：
DeRosa, M. [1 ]
Cocks, K. [2 ]
Taylor, F. [1 ]
Bobiak, S. [3 ]
Garcia, Juarez A. [3 ]
Shaw, J. W. [3 ]
机构：
[1] Adelphi Values, Boston, MA USA
[2] Adelphi Mill, Bollington, England
[3] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN149
引用
收藏
页码：A113 / A113
页数：1
相关论文
共 50 条
  • [1] ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTHCARE RESOURCE UTILIZATION (HCRU) IN CHECKMATE 141, A PHASE 3 STUDY OF NIVOLUMAB VERSUS INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) PLATINUM-REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    DeRosa, M.
    Cocks, K.
    Korytowsky, B.
    Contente, M.
    Taylor, F.
    Shaw, J. W.
    VALUE IN HEALTH, 2017, 20 (09) : A447 - A447
  • [2] Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and Updated Safety and Efficacy
    Gillison, Maura L.
    Blumenschein, George, Jr.
    Fayette, Jerome
    Guigay, Joel
    Colevas, A. Dimitrios
    Licitra, Lisa
    Harrington, Kevin J.
    Kasper, Stefan
    Vokes, Everett E.
    Even, Caroline
    Worden, Francis
    Saba, Nabil F.
    Iglesias Docampo, Lara Carmen
    Haddad, Robert
    Rordorf, Tamara
    Kiyota, Naomi
    Tahara, Makoto
    Lynch, Mark
    Kopit, Justin
    Ferris, Robert L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 144 - 144
  • [3] Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.
    Ferris, Robert L.
    Blumenschein, George R.
    Fayette, Jerome
    Guigay, Joel
    Colevas, A. Dimitrios
    Licitra, Lisa F.
    Harrington, Kevin J.
    Kasper, Stefan
    Vokes, Everett E.
    Even, Caroline
    Worden, Francis P.
    Haddad, Robert I.
    Kiyota, Naomi
    Tahara, Makoto
    Monga, Manish
    Lynch, MarkJohn
    Geese, William J.
    Kopit, Justin
    Shaw, James W.
    Gillison, Maura L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Nivolumab vs Investigator'S Choice (IC) in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
    Ferris, Robert L.
    Licitra, Lisa
    Fayette, Jerome
    Even, Caroline
    Blumenschein, George, Jr.
    Harrington, Kevin J.
    Guigay, Joel
    Vokes, Everett E.
    Saba, Nabil F.
    Haddad, Robert
    Ramkumar, Shanmugasundaram
    Russell, Jeffery
    Brossart, Peter
    Tahara, Makoto
    Monga, Manish
    Zhu, Jin
    Colevas, A. Dimitrios
    Gillison, Maura L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 143 - 143
  • [5] Nivolumab (nivo) vs investigator's choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.
    Saba, Nabil F.
    Blumenschein, George R.
    Guigay, Joel
    Licitra, Lisa F.
    Fayette, Jerome
    Harrington, Kevin J.
    Kiyota, Naomi
    Gillison, Maura L.
    Ferris, Robert L.
    Jayaprakash, Vijayvel
    Lynch, Mark John
    Li, Li
    Brossart, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141
    Gillison, Maura L.
    Blumenschein, George
    Fayette, Jerome
    Guigay, Joel
    Colevas, A. Dimitrios
    Licitra, Lisa
    Harrington, Kevin
    Kasper, Stefan
    Vokes, Everett E.
    Even, Caroline
    Worden, Francis
    Saba, Nabil F.
    Docampo, Lara Carmen Iglesias
    Haddad, Robert
    Rordorf, Tamara
    Kiyota, Naomi
    Tahara, Makoto
    Monga, Manish
    Lynch, Mark
    Geese, William J.
    Schactman, Mark
    Kopit, Justin
    Shaw, James W.
    Ferris, Robert L.
    CANCER RESEARCH, 2016, 76
  • [7] Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (nivo) or investigator's choice (IC): CheckMate 141
    Harrington, K.
    Ferris, R. L.
    Shaw, J.
    Taylor, F.
    Derosa, M.
    Turner-Bowker, D.
    Morrissey, L.
    Cocks, K.
    Kiyota, N.
    Gillison, M.
    Guigay, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Patient-reported outcomes (PROs) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) treated with nivolumab (Nivo) or Investigator's Choice (IC): CheckMate 141
    Kiyota, N.
    Harrington, K.
    Ferris, R. L.
    Shaw, J. W.
    Taylor, F.
    Derosa, M.
    Turner-Bowker, D.
    Morrissey, L.
    Cocks, K.
    Gillison, M.
    Guigay, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Nivolumab vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141
    Licitra, L.
    Ferris, R. L.
    Blumenschein, G., Jr.
    Harrington, K. J.
    Guigay, J.
    Kasper, S.
    Saba, N. F.
    Haddad, R.
    Kiyota, N.
    Monga, M.
    Lynch, M.
    Li, L.
    Gillison, M. L.
    Fayette, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Nivolumab (Nivo) vs investigator's choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.
    Gillison, Maura L.
    Blumenschein, George R.
    Fayette, Jerome
    Guigay, Joel
    Colevas, A. Dimitrios
    Licitra, Lisa
    Harrington, Kevin
    Kasper, Stefan
    Vokes, Everett E.
    Even, Caroline
    Worden, Francis P.
    Saba, Nabil F.
    Docampo, Lara Carmen Iglesias
    Haddad, Robert I.
    Rordorf, Tamara
    Kiyota, Naomi
    Tahara, Makoto
    Lynch, Mark John
    Kopit, Justin
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345